利洛托单抗
![本页使用了标题或全文手工转换](http://images.weserv.nl/?url=//upload.wikimedia.org/wikipedia/commons/thumb/c/cd/Zh_conversion_icon_m.svg/35px-Zh_conversion_icon_m.svg.png)
单克隆抗体 | |
---|---|
种类 | 完整抗体 |
目标 | CD37 |
临床资料 | |
其他名称 | 替妥洛单抗、HH1 |
ATC码 |
|
识别信息 | |
CAS号 | 1453362-55-4(1453362-90-7 (沙镥(177Lu)利洛托单抗)) |
ChemSpider |
|
UNII | |
KEGG |
利洛托单抗(INN:Lilotomab),前称替妥洛单抗(tetulomab)或HH1,[1]是针对 CD37 的鼠单克隆抗体,[2]CD37是一种在成熟人类 B 细胞表面表达的糖蛋白。[3]它首次在挪威镭医院生成的。[3]
截至2016年,挪威公司Nordic Nanovector ASA正在开发一种放射免疫治疗药物,其中利洛托单抗通过一种名为satetraxetan(DOTA的衍生物)的连接体与发射β辐射的同位素镥-177结合。[2]该化合物称为177Lu-HH1或沙镥(177Lu)利洛托单抗(INN:Lutetium (177Lu) lilotomab satetraxetan,商品名Betalutin)。[1]截至2016年,针对非霍奇金淋巴瘤患者的1/2期临床试验正在进行中。[4]
![](http://images.weserv.nl/?url=//upload.wikimedia.org/wikipedia/commons/thumb/d/dc/Lutetium-177_satetraxetan.svg/330px-Lutetium-177_satetraxetan.svg.png)
参考资料
- ^ 1.0 1.1 Lutetium (177lu) lilotomab satetraxetan - Nordic Nanovector. Adis Insight. Springer Nature Switzerland AG. [1 September 2016]. (原始内容存档于2024-03-04).
- ^ 2.0 2.1 Recommended INN List 74 (PDF). WHO Drug Information. 2015, 29 (3) [2024-03-03]. (原始内容存档 (PDF)于2017-04-02).
- ^ 3.0 3.1 Robak T, Robak P. Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opinion on Biological Therapy. May 2014, 14 (5): 651–61. PMID 24555705. S2CID 19987961. doi:10.1517/14712598.2014.890182.
- ^ EudraCT Number: 2011-000033-36. EU Clinical Trials Registry. [2024-03-03]. (原始内容存档于2024-03-03).
Treatment of lymphoma with targeted internal radiation therapy (Betalutin)
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112 (PDF). WHO Drug Information. 2014, 28 (4): 515.
延伸阅读
- Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Current Radiopharmaceuticals. March 2013, 6 (1): 20–7. PMC 3624777
. PMID 23256748. doi:10.2174/1874471011306010004.
|